In Vitro Lipolysis Data Does Not Adequately Predict the In Vivo Performance of Lipid-Based Drug Delivery Systems Containing Fenofibrate

The present study investigated the utility of in vitro lipolysis performance indicators drug solubilization and maximum supersaturation ratio (SRM) for their predictive use for the in vivo performance in a minipig model. The commercial Lipanthyl formulation and a series of LbDDS based on identical self-nanoemulsifying drug delivery systems (SNEDDS) containing 200 mg of fenofibrate, either dissolved or suspended, were subjected to combined gastric (pH 2) and intestinal (pH 6.5) in vitro lipolysis. Based on the solubilization profiles and SRM the rank-order SNEDDS (75% drug load) > super-SNEDDS (150% drug load, dissolved) = SNEDDS suspension (150% drug load, partially suspended) > Lipanthyl was established, with an increased likelihood of drug precipitation above SRM > 3. The in vitro performance, however, was not reproduced in vivo in a minipig model as the mean plasma concentration over time curves of all LbDDS were comparable, independent of the initial physical state of the drug. There was no correlation between the area under the solubilization-time curves (AUCin vitro) of the intestinal step and the AUCin vivo. The study suggests careful interpretation of in vitro performance criteria and revision of LbDDS optimization towards increased solubilization.

[1]  M. Hossain,et al.  Gastrointestinal Transit of Nondisintegrating, Nonerodible Oral Dosage Forms in Pigs , 1990, Pharmaceutical Research.

[2]  C. Pouton,et al.  Enhancing intestinal drug solubilisation using lipid-based delivery systems. , 2008, Advanced drug delivery reviews.

[3]  A. Müllertz,et al.  Biorelevant media simulating fed state intestinal fluids: colloid phase characterization and impact on solubilization capacity. , 2010, Journal of pharmaceutical sciences.

[4]  Alan B. Watts,et al.  Formulating Poorly Water Soluble Drugs , 2012, AAPS Advances in the Pharmaceutical Sciences Series.

[5]  J. Caldwell,et al.  The metabolism and disposition of fenofibrate in rat, guinea pig, and dog. , 1988, Drug metabolism and disposition: the biological fate of chemicals.

[6]  G. Edwards,et al.  Lipid digestion as a trigger for supersaturation: evaluation of the impact of supersaturation stabilization on the in vitro and in vivo performance of self-emulsifying drug delivery systems. , 2012, Molecular pharmaceutics.

[7]  Anette Müllertz,et al.  Lipid-based Formulations for Danazol Containing a Digestible Surfactant, Labrafil M2125CS: In Vivo Bioavailability and Dynamic In Vitro Lipolysis , 2008, Pharmaceutical Research.

[8]  C. Pouton,et al.  Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[9]  T. Rades,et al.  Influence of lipid composition and drug load on the In Vitro performance of self-nanoemulsifying drug delivery systems. , 2012, Journal of pharmaceutical sciences.

[10]  J. Sims,et al.  The utility of the minipig as an animal model in regulatory toxicology. , 2010, Journal of pharmacological and toxicological methods.

[11]  Bruno Sarmento,et al.  Models to predict intestinal absorption of therapeutic peptides and proteins. , 2012, Current drug metabolism.

[12]  G. Edwards,et al.  Increasing the Proportional Content of Surfactant (Cremophor EL) Relative to Lipid in Self-emulsifying Lipid-based Formulations of Danazol Reduces Oral Bioavailability in Beagle Dogs , 2007, Pharmaceutical Research.

[13]  Xing Tang,et al.  In vitro and in vivo evaluation of fenofibrate solid dispersion prepared by hot-melt extrusion , 2010, Drug development and industrial pharmacy.

[14]  Patrick Augustijns,et al.  The conflict between in vitro release studies in human biorelevant media and the in vivo exposure in rats of the lipophilic compound fenofibrate. , 2011, International journal of pharmaceutics.

[15]  R. Verger,et al.  Secretion and contribution to lipolysis of gastric and pancreatic lipases during a test meal in humans. , 1993, Gastroenterology.

[16]  Anette Müllertz,et al.  Fed and fasted state gastro-intestinal in vitro lipolysis: In vitro in vivo relations of a conventional tablet, a SNEDDS and a solidified SNEDDS. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[17]  B. Griffin,et al.  Comparison of in vitro tests at various levels of complexity for the prediction of in vivo performance of lipid-based formulations: case studies with fenofibrate. , 2014, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[18]  Ben J. Boyd,et al.  Susceptibility to Lipase-Mediated Digestion Reduces the Oral Bioavailability of Danazol After Administration as a Medium-Chain Lipid-Based Microemulsion Formulation , 2004, Pharmaceutical Research.

[19]  B. Sarmento,et al.  Towards the characterization of an in vitro triple co-culture intestine cell model for permeability studies. , 2013, International journal of pharmaceutics.

[20]  Jennifer B Dressman,et al.  Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[21]  B. Abrahamsson,et al.  Oral bioavailability of cinnarizine in dogs: relation to SNEDDS droplet size, drug solubility and in vitro precipitation. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[22]  Giulia Bonacucina,et al.  Colloidal soft matter as drug delivery system. , 2009, Journal of pharmaceutical sciences.

[23]  A. Müllertz,et al.  Toward the establishment of standardized in vitro tests for lipid-based formulations. 2. The effect of bile salt concentration and drug loading on the performance of type I, II, IIIA, IIIB, and IV formulations during in vitro digestion. , 2012, Molecular pharmaceutics.

[24]  Hywel D Williams,et al.  Strategies to Address Low Drug Solubility in Discovery and Development , 2013, Pharmacological Reviews.

[25]  Jennifer Dressman Oral Lipid-Based Formulations: Enhancing the Bioavailability of Poorly Water-Soluble Drugs , 2007 .

[26]  B. Boyd Characterisation of drug release from cubosomes using the pressure ultrafiltration method. , 2003, International journal of pharmaceutics.

[27]  T. Rades,et al.  Precipitation of a poorly soluble model drug during in vitro lipolysis: characterization and dissolution of the precipitate. , 2010, Journal of pharmaceutical sciences.

[28]  Thomas Rades,et al.  Supersaturated Self-Nanoemulsifying Drug Delivery Systems (Super-SNEDDS) Enhance the Bioavailability of the Poorly Water-Soluble Drug Simvastatin in Dogs , 2012, The AAPS Journal.

[29]  A. Müllertz,et al.  Toward the establishment of standardized in vitro tests for lipid-based formulations, part 1: method parameterization and comparison of in vitro digestion profiles across a range of representative formulations. , 2012, Journal of pharmaceutical sciences.

[30]  Susan A. Barker,et al.  The Effect of Composition and Gastric Conditions on the Self-Emulsification Process of Ibuprofen-Loaded Self-Emulsifying Drug Delivery Systems: A Microscopic and Dynamic Gastric Model Study , 2011, Pharmaceutical Research.

[31]  F. Carrière,et al.  In Vitro Gastrointestinal Lipolysis of Four Formulations of Piroxicam and Cinnarizine with the Self Emulsifying Excipients Labrasol® and Gelucire® 44/14 , 2009, Pharmaceutical Research.

[32]  A Müllertz,et al.  A dynamic in vitro lipolysis model. I. Controlling the rate of lipolysis by continuous addition of calcium. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[33]  A. Müllertz,et al.  Toward the Establishment of Standardized In Vitro Tests for Lipid-Based Formulations, Part 3: Understanding Supersaturation Versus Precipitation Potential During the In Vitro Digestion of Type I, II, IIIA, IIIB and IV Lipid-Based Formulations , 2013, Pharmaceutical Research.

[34]  Thomas Rades,et al.  Characterising Lipid Lipolysis and Its Implication in Lipid-Based Formulation Development , 2012, The AAPS Journal.

[35]  R Holm,et al.  Supersaturated Self-Nanoemulsifying Drug Delivery Systems (super-SNEDDS) , 2012 .

[36]  D. Hauss,et al.  Oral lipid-based formulations : enhancing the bioavailability of poorly water-soluable drugs , 2007 .

[37]  C. Pouton,et al.  Design of lipid-based formulations for oral administration of poorly water-soluble drugs: precipitation of drug after dispersion of formulations in aqueous solution. , 2009, Journal of pharmaceutical sciences.

[38]  A. Müllertz,et al.  In vitro lipolysis models as a tool for the characterization of oral lipid and surfactant based drug delivery systems. , 2011, International journal of pharmaceutics.

[39]  S. S. Davis,et al.  Gastrointestinal transit of dosage forms in the pig , 2001, The Journal of pharmacy and pharmacology.

[40]  Ping Li,et al.  Developing early formulations: practice and perspective. , 2007, International journal of pharmaceutics.

[41]  G. Edwards,et al.  Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs. , 2008, Journal of pharmaceutical sciences.

[42]  M. Brandl,et al.  In‐vitro permeability of poorly water soluble drugs in the phospholipid vesicle‐based permeation assay: the influence of nonionic surfactants , 2011, The Journal of pharmacy and pharmacology.

[43]  F. Carrière,et al.  In Vitro Digestion of the Self-Emulsifying Lipid Excipient Labrasol® by Gastrointestinal Lipases and Influence of its Colloidal Structure on Lipolysis Rate , 2013, Pharmaceutical Research.

[44]  Thierry F. Vandamme,et al.  Nano-emulsions and Micro-emulsions: Clarifications of the Critical Differences , 2011, Pharmaceutical Research.

[45]  Anna Juréus,et al.  Bioavailability of Cinnarizine in Dogs: Effect of SNEDDS Loading Level and Correlation with Cinnarizine Solubilization During In Vitro Lipolysis , 2013, Pharmaceutical Research.

[46]  Claus-Michael Lehr,et al.  Soluplus® as an effective absorption enhancer of poorly soluble drugs in vitro and in vivo. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[47]  G Vergnault,et al.  Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug. , 2007, Advanced drug delivery reviews.

[48]  S. Stegemann,et al.  When poor solubility becomes an issue: from early stage to proof of concept. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.